Theranostics is the combination of tumor-specific targeted radionuclide imaging and therapy.
The Ahmanson Translational Theranostics Division (ATTD) is a Division of the Department of Molecular and Medical Pharmacology (DMMP). The Division includes the Nuclear Medicine clinic, the Biomedical Cyclotron, as well as basic and translational research groups and labs. Fueled by the adoption of Positron Emission Tomography (PET/CT) and stimulated by major new Theranostics and therapeutic opportunities in prostate cancer and neuroendocrine tumors, the Division and Nuclear Medicine clinic has expanded significantly. Novel therapeutic approaches, together with advanced molecular imaging assays, have given rise to the field of Theranostics, the combination of tumor-specific targeted radionuclide imaging and therapy. Very specific clinical and research expertise is now required to master all aspects of Nuclear Medicine, Molecular Imaging and Theranostics.
Dr. Jeremie Calais MD MSc has established a clinical Theranostics research program that combines academic investigator-initiated and industry sponsored studies using targeted radionuclide imaging and therapy. The clinical research program focuses on translatable radiolabeled theranostic pairs that can be used and applied for diagnosis and therapy of cancer. We collaborate closely with clinical faculty across many departments at UCLA (Urology, Radiation Oncology, Radiology, Medical Oncology, Oncologic Surgery) but also with multiple national and international collaborators. Our group has submitted jointly with UCSF an academic NDA for 68Ga-PSMA-11, a major achievement for academia.
Jeremie Calais MD MSc
Dr. Jeremie Calais is Associate Professor and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA. He is also a member of the Jonsson Comprehensive Cancer Center and the UCLA Institute of Urologic Oncology. Dr. Calais received his MD degree from the University of Paris-Diderot in 2010. He subsequently trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center of the University of Rouen and was board certified by the French Society of Nuclear Medicine in 2014. His work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches. He uses PET/CT imaging for cancer phenotyping, radiation therapy planning and therapy response assessment. He was mentored by Dr. Johannes Czernin and is now one of the leading prostate cancer imaging and theranostics researchers. He leads the clinical theranostics research program at UCLA that combines radionuclide therapy and imaging. He now serves as Principal Investigator of randomized prospective phase 2 and 3 clinical trials
Figure 1: Examples of pioneering publications in PSMA related Theranostics research